KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Long-Term Debt Repayments (2017 - 2024)

Pacific Biosciences Of California (PACB) has 5 years of Long-Term Debt Repayments data on record, last reported at $152000.0 in Q2 2024.

  • For Q2 2024, Long-Term Debt Repayments fell 67.31% year-over-year to $152000.0; the TTM value through Mar 2025 reached $152000.0, down 91.23%, while the annual FY2024 figure was $490000.0, 73.4% down from the prior year.
  • Long-Term Debt Repayments reached $152000.0 in Q2 2024 per PACB's latest filing, down from $338000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $16.0 million in Q1 2020 and bottomed at $152000.0 in Q2 2024.
  • Average Long-Term Debt Repayments over 4 years is $1.8 million, with a median of $428000.0 recorded in 2022.
  • Peak YoY movement for Long-Term Debt Repayments: grew 18.54% in 2023, then plummeted 67.31% in 2024.
  • A 4-year view of Long-Term Debt Repayments shows it stood at $16.0 million in 2020, then crashed by 97.32% to $428000.0 in 2022, then rose by 3.97% to $445000.0 in 2023, then tumbled by 65.84% to $152000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Long-Term Debt Repayments were $152000.0 in Q2 2024, $338000.0 in Q1 2024, and $445000.0 in Q4 2023.